Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Cash & Equivalents

Cash & Equivalents at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$197.66M+234%
Viatris logo
ViatrisVTRS
$1.81B+139%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
ALN
Alnylam PharmaceuticalsALNY
$1.71B+67.5%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$41.01M-38.3%
Amgen logo
AmgenAMGN
$559M+10.0%

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×—
P/S2×-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%—
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's cash & equivalents?
ANI Pharmaceuticals (ANIP) reported cash & equivalents of $311.21M in Q1 2026.
How has ANI Pharmaceuticals's cash & equivalents changed year-over-year?
ANI Pharmaceuticals's cash & equivalents increased by 107.7% year-over-year, from $149.84M to $311.21M.
What is the long-term trend for ANI Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's cash & equivalents has grown at a 105.1% compound annual growth rate (CAGR), from $7.86M to $285.62M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.